Past FDA Action Is Not Necessarily Predictive Of Future Behavior – Temple
Executive Summary
Sponsors should not assume clinical trials are immune from evaluation according to updated efficacy standards, even if parameters are initially agreed upon with the agency
You may also be interested in...
Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded
FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications
Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded
FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications
Factive Should Be Used Second-Line For Treatment Of Acute Sinusitis – Cmte.
Oscient's Factive would be a second-line treatment of acute bacterial sinusitis, FDA's Anti-Infective Drugs Advisory Committee said in recommending against approval of a supplemental claim for gemifloxacin in ABS Sept. 12.